-

11:04:54 AM

Latest XAIR Stock Market News

XAIR - Beyond Air Inc

06/10/21 4:05 PM

Nasdaq : XAIR

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021

Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit ® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial launch in the fourth quarter of calendar year 2021 Expanded the commercial and business

RHEA-AI

very positive

05/26/21 7:30 AM

Nasdaq : XAIR

Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

very positive

05/25/21 7:30 AM

Nasdaq : XAIR

Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with

RHEA-AI

neutral

05/20/21 8:00 AM

Nasdaq : XAIR

Beyond Air® Strengthens Commercial Leadership Team with Appointments of Head of Sales and Head of Marketing

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and

RHEA-AI

very positive

05/13/21 8:00 AM

Nasdaq : XAIR

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021

I nterim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit ® PRO is well-tolerated with no treatment-related adverse events, and demonstrates encouraging efficacy signals Further

RHEA-AI

neutral

05/03/21 8:00 AM

Nasdaq : XAIR

Beyond Air® Appoints Peter Senior as Director of Business Development

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing

RHEA-AI

neutral

04/14/21 8:00 AM

Nasdaq : XAIR

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

03/24/21 8:00 AM

Nasdaq : XAIR

Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary

RHEA-AI

neutral

03/01/21 8:00 AM

Nasdaq : XAIR

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

02/16/21 8:00 AM

Nasdaq : XAIR

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients Beyond Air recently initiated a pilot study using LungFit™ GO for at-home self-administration of up to

RHEA-AI

neutral

XAIR Data

industryOther Industrial Machinery Manufacturing
websitewww.ait-pharm.com
ceoSteven Lisi
security nameBeyond Air Inc
issue typecs
sectorManufacturing
sic code3841
employees
tagsTechnology Services,Packaged Software,Manufacturing,Other Industrial Machinery Manufacturing
address825 E Gate Blvd Ste 320
address2
stateNew York
cityGarden City
zip11530-2135
countryUS
phone15166658200

XAIR Description:

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.